Adaptive Biotechnologies (ADPT) EBIT (2018 - 2026)

Adaptive Biotechnologies has disclosed EBIT across 9 years of filings, most recently posting -$15.8 million for Q2 2026.

• In Q2 2026, EBIT rose 37.01% year-over-year to -$15.8 million; the TTM figure through Jun 2026 stood at -$37.5 million (up 69.07% YoY), while the FY2025 annual figure was -$57.1 million, up 64.86% from the prior year.
• EBIT came in at -$15.8 million for Q2 2026 at Adaptive Biotechnologies, up from -$19.2 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $10.3 million in Q3 2025 to a low of -$71.1 million in Q4 2023.
• Average EBIT over 5 years is -$37.9 million, with a median of -$42.3 million recorded in 2022.
• Year-over-year, EBIT tumbled 81.36% in 2023 and jumped 131.53% in 2025.
• Over 5 years, EBIT stood at -$39.2 million in 2022, then plunged by 81.36% to -$71.1 million in 2023, then surged by 52.39% to -$33.8 million in 2024, then surged by 62.25% to -$12.8 million in 2025, then decreased by 23.46% to -$15.8 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$15.8 million in Q2 2026, -$19.2 million in Q1 2026, and -$12.8 million in Q4 2025.